Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Evaluate wide market index fund performance against the SP 500 in retirement planning, emphasizing return consistency and fee impact.
28,313 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
New research finds america pays workers just a fraction of the country’s wealth, a share that trails most OECD peers ...
As 1stdibs gears up for 2025 earnings, investors crave clarity on growth, profitability, and sustainable margins. Thi...
The White House announced a temporary waiver of the Jones Act to boost crude shipments between U.S. ports. Early mark...
The Navy's new 30-year shipbuilding plan calls for 15 Trump-Class battleships by 2055, with per-ship costs near $14.5...
In a high-rate environment, Verizon’s steady cash flow and dividend attract institutional buyers. Here’s why it’s gai...
A wrist-worn hormone monitor backed by a $11 million seed round aims to turn hormone tracking into everyday wellness....
Warren Buffett has paused his annual gift to the Gates Foundation, signaling a shift in a years-long philanthropic pa...
BitMine posted a strong ETH staking quarter, but a large derivatives loss erased gains, underscoring risk in its Ethe...
If you’re evaluating FLR, you’re weighing big projects, complex contracts, and a shifting risk profile. This guide br...
CBS News is shuttering its radio news service as part of broad layoffs, ending a nearly 100-year run. The move aims t...
Dividend income can be a steady stream, but payouts can change. This article flags three dividend stocks that could c...